KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Retained Earnings (2016 - 2025)

Gsk (GSK) has 9 years of Retained Earnings data on record, last reported at $10.0 billion in Q4 2024.

  • For Q4 2024, Retained Earnings rose 11.37% year-over-year to $10.0 billion; the TTM value through Dec 2024 reached $10.0 billion, up 11.37%, while the annual FY2024 figure was $10.0 billion, 10.68% up from the prior year.
  • Retained Earnings reached $10.0 billion in Q4 2024 per GSK's latest filing, up from $9.0 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $10.0 billion in Q4 2024 and bottomed at $2.8 billion in Q4 2020.
  • Average Retained Earnings over 5 years is $6.0 billion, with a median of $5.1 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: decreased 7.15% in 2020, then soared 78.31% in 2022.
  • A 5-year view of Retained Earnings shows it stood at $2.8 billion in 2020, then increased by 2.09% to $2.9 billion in 2021, then skyrocketed by 78.31% to $5.1 billion in 2022, then surged by 75.57% to $9.0 billion in 2023, then grew by 11.37% to $10.0 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $10.0 billion in Q4 2024, $9.0 billion in Q4 2023, and $5.1 billion in Q4 2022.